Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853.
Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):E3106-E3115. doi: 10.1073/pnas.1718341115. Epub 2018 Mar 19.
Many microbial pathogens produce a β-(1→6)-linked poly--acetyl-d-glucosamine (PNAG) surface capsule, including bacterial, fungal, and protozoan cells. Broadly protective immune responses to this single conserved polysaccharide antigen in animals are possible but only when a deacetylated poly--acetyl-d-glucosamine (dPNAG; <30% acetate) glycoform is administered as a conjugate to a carrier protein. Unfortunately, conventional methods for natural extraction or chemical synthesis of dPNAG and its subsequent conjugation to protein carriers can be technically demanding and expensive. Here, we describe an alternative strategy for creating broadly protective vaccine candidates that involved coordinating recombinant poly--acetyl-d-glucosamine (rPNAG) biosynthesis with outer membrane vesicle (OMV) formation in laboratory strains of The glycosylated outer membrane vesicles (glycOMVs) released by these engineered bacteria were decorated with the PNAG glycopolymer and induced high titers of PNAG-specific IgG antibodies after immunization in mice. When a enzyme responsible for PNAG deacetylation was additionally expressed in these cells, glycOMVs were generated that elicited antibodies to both highly acetylated PNAG (∼95-100% acetate) and a chemically deacetylated dPNAG derivative (∼15% acetate). These antibodies mediated efficient in vitro killing of two distinct PNAG-positive bacterial species, namely and subsp. , and mice immunized with PNAG-containing glycOMVs developed protective immunity against these unrelated pathogens. Collectively, our results reveal the potential of glycOMVs for targeting this conserved polysaccharide antigen and engendering protective immunity against the broad range of pathogens that produce surface PNAG.
许多微生物病原体都产生β-(1→6)连接的多乙酰-d-葡聚糖(PNAG)表面胶囊,包括细菌、真菌和原生动物细胞。在动物中,针对这种单一保守多糖抗原产生广泛保护的免疫反应是可能的,但只有当去乙酰化的多乙酰-d-葡聚糖(dPNAG;<30%醋酸酯)糖型作为缀合物施用于载体蛋白时才有可能。不幸的是,天然提取或化学合成 dPNAG 及其随后与蛋白载体缀合的常规方法可能在技术上具有挑战性且昂贵。在这里,我们描述了一种创建广泛保护性疫苗候选物的替代策略,该策略涉及协调重组多乙酰-d-葡聚糖(rPNAG)生物合成与实验室菌株中 的外膜囊泡(OMV)形成。这些经过工程改造的细菌释放的糖基化外膜囊泡(glycOMVs)被 PNAG 糖聚合物装饰,并在小鼠中免疫后诱导出高滴度的 PNAG 特异性 IgG 抗体。当在这些细胞中另外表达负责 PNAG 去乙酰化的 酶时,会产生生成既针对高度乙酰化的 PNAG(约 95-100%醋酸酯)又针对化学去乙酰化的 dPNAG 衍生物(约 15%醋酸酯)的抗体。这些抗体介导了针对两种不同的 PNAG 阳性细菌物种,即 和 亚种的有效体外杀伤,并且用含有 PNAG 的 glycOMVs 免疫的小鼠对这些无关的病原体产生了保护性免疫。总的来说,我们的结果揭示了 glycOMVs 靶向这种保守多糖抗原并引发针对产生表面 PNAG 的广泛病原体的保护性免疫的潜力。